Results 91 to 100 of about 28,054 (245)

LRRK2 in Parkinson's disease and dementia with Lewy bodies

Molecular Neurodegeneration, 2006
Background Mutations in LRRK2 encoding leucine-rich repeat kinase 2 are thus far the most frequent genetic cause associated with autosomal dominant and idiopathic Parkinson's disease (PD).
Zhu Xiongwei, Babar Asim, Siedlak Sandra L, Yang Qiwei, Ito Genta, Iwatsubo Takeshi, Smith Mark A, Perry George, Chen Shu G   +8 more
doaj   +1 more source

LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons

Journal of Parkinson’s Disease, 2021
Background: Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson’s disease (PD) and are also associated with genetic risk in idiopathic PD.
Michael X. Henderson, Lakshmi Changolkar, John Q. Trojanowski, Virginia M.Y. Lee   +3 more
doaj   +1 more source

Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is a worldwide, complex neurodegenerative disorder influenced by both genetic and environmental factors. Around 15–20% of PD cases are linked to genetic mutations, providing insights into the disease's pathogenesis.
Chiara Meneghini, Luca Gallo, Arianna Sala, Enza Maria Valente, Micol Avenali, Silvia Paola Caminiti   +5 more
wiley   +1 more source

Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily [PDF]

, 2017
Mutations in LRRK2 cause autosomal dominant Parkinson's disease (PD). LRRK2 encodes a multi-domain protein containing GTPase and kinase domains, and putative protein-protein interaction domains.
Bandopadhyay, Rina, Biskup, Saskia, Dawson, Ted M., Dawson, Valina L., Glauser, Liliane, Jones, Amy, Moore, Darren J., Moser, Roger, Musso, Alessandra, Stafa, Klodjan, Tsika, Elpida, Xiong, Yulan   +11 more
core  

Brain Penetrant LRRK2 Inhibitor

ACS Medicinal Chemistry Letters, 2012
Activating mutations in leucine-rich repeat kinase 2 (LRRK2) are present in a subset of Parkinson's disease (PD) patients and may represent an attractive therapeutic target. Here we report a 2-anilino-4-methylamino-5-chloropyrimidine, HG-10-102-01(4) is a potent and selective inhibitor of wild-type LRRK2 and the G2019S mutant.
Choi, Hwan Geun, Zhang, Jin-Wei, Deng, Xianming, Hatcher, JM, Patricelli, MP, Zhao, Z, Alessi, DR, Gray, NS   +7 more
openaire   +4 more sources

LRRK2 pathobiology in Parkinson's disease [PDF]

Journal of Neurochemistry, 2014
AbstractMutations in the catalytic Roc‐COR and kinase domains of leucine‐rich repeat kinase 2 (LRRK2) are a common cause of familial Parkinson's disease (PD). LRRK2 mutations cause PD with age‐related penetrance and clinical features identical to late‐onset sporadic PD.
Ian, Martin, Jungwoo Wren, Kim, Valina L, Dawson, Ted M, Dawson   +3 more
openaire   +2 more sources

Screening for chemical modulators for LRRK2 [PDF]

, 2016
After the discovery of leucine-rich repeat kinase 2 (LRRK2) as a risk factor for sporadic Parkinson's disease (PD) and mutations in LRRK2 as a cause of some forms of familial PD, there has been substantial interest in finding chemical modulators of LRRK2
Angeles, Chen, Covy, Csöbönyeiová, Cui, Deng, Dorsey, Estrada, Fell, Garofalo, Garofalo, Godena, Greshock, Grünewald, Guo, Göring, Hatcher, Heather Mortiboys, Henderson, Hermanson, Ho, Kotz, Lang, Lee, Leveridge, Lewis, Li, Li, Li, Liu, Lovitt, Macarrón, Mendivil-Perez, Mortiboys, Mortiboys, Mortiboys, Niu, Papkovskaia, Pedro, Perera, Powell, Ramsden, Reith, Rudenko, Shrader, Sirenko, Steger, Troxler, Wang, West, Yun, Zhang   +51 more
core   +1 more source

The role of the LRRK2 gene in Parkinsonism [PDF]

Molecular Neurodegeneration, 2014
Parkinson's disease (PD), like many common age-related conditions, has been recognized to have a substantial genetic component. Multiple lines of evidence suggest that Leucine-rich repeat kinase 2 (LRRK2) is a crucial factor to understanding the etiology of PD. LRRK2 is a large, widely expressed, multi-domain and multifunctional protein.
Li, Jie-Qiong, Tan, Lan, Yu, Jin-Tai
openaire   +2 more sources

Pharmacology of LRRK2 with type I and II kinase inhibitors revealed by cryo-EM

Cell Discovery
LRRK2 is one of the most promising drug targets for Parkinson’s disease. Though type I kinase inhibitors of LRRK2 are under clinical trials, alternative strategies like type II inhibitors are being actively pursued due to the potential undesired effects ...
Hanwen Zhu, Patricia Hixson, Wen Ma, Ji Sun   +3 more
doaj   +1 more source

Biomarkers of Leucine‐Rich Repeat Kinase 2 (LRRK2) and Lysosomal Dysfunction in Progressive Supranuclear Palsy

Movement Disorders, EarlyView.
Abstract Background Common and rare genetic variants in leucine‐rich repeat kinase 2 (LRRK2) have been linked with sporadic and familial Parkinson's disease (PD). Recently, we discovered that common genetic variation near the LRRK2 locus determined survival in progressive supranuclear palsy (PSP).
Louise‐Kristine Nielsen, Joshua L.I. Frost, David P. Vaughan, Raquel Real, Riona Fumi, Marte Theilmann Jensen, Megan Hodgson, Eleanor J. Stafford, Lesley Wu, Olaf Ansorge, Annelies Quaegebeur, Kieren S.J. Allinson, Thomas T. Warner, Zane Jaunmuktane, Anjum Misbahuddin, P. Nigel Leigh, Boyd C.P. Ghosh, Kailash P. Bhatia, Alistair Church, Christopher Kobylecki, Michele T.M. Hu, James B. Rowe, Alan A. Shomo, Danielle L. Graham, Omar S. Mabrouk, Huw R. Morris, Esther M. Sammler, Edwin Jabbari   +27 more
wiley   +1 more source